{'fraction_non_alphanumeric': 0.026690391459074734, 'fraction_numerical': 0.0035587188612099642, 'mean_word_length': 6.217948717948718, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression of chondroitin‐glucuronate C5‐epimerase and cellular immune responses in patients with hepatocellular carcinoma

Chondroitin‐glucuronate C5‐epimerase is an enzyme that converts D‐glucuronic acid to L‐iduronic acid residues in dermatan sulphate biosynthesis. It is also identified to be a tumour‐associated antigen recognized by cytotoxic T cells (CTLs) and its enhanced expression in many cancers has been reported. In the present study, we investigated the usefulness of this molecule as an immunotherapeutic target in hepatocellular carcinoma (HCC).